This could also be India's first vaccine for children aged 12 years and above as the company has conducted trials on the age group. The decision, however, lies with the regulator, reports Sohini Das
China will carry out major scientific research to enhance its biosecurity science and technological capacity against future infectious diseases, state-run Global Times quoted Xiang as saying.
In September, Bharat Biotech aimed to supply 35 million doses, and take this up to 55 million by October. This is still less than what the Indian government expects from the company.
